metformin

Telomere length, frailty and death

Latest articles

Dyno Therapeutics closes $100m to accelerate gene therapy

Dyno Therapeutics closes $100 million Series A led by Andreessen Horowitz to accelerate AI-powered gene therapy platform. Dyno Therapeutics, Inc, a biotech applying AI to...

Sticking with glutathione could be a smart longevity choice

The body's "master antioxidant" glutathione is a powerful weapon in the fight for longevity, but it diminishes with age; AgelessRx has a range of...

Rise of the retrons – a new gene editing technique

Move over CRISPR... a new gene editing technique enables millions of genetic experiments to be performed simultaneously. Like the best B Movie ever, The Day...

VitaDAO announces “Longevity Molecule” research project

VitaDAO will use advanced machine learning to crunch the data from 1.04 billion prescriptions to understand the impact of drugs on human lifespan. VitaDAO, which...

Most read

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

Spermidine: the mind-enhancing supplement

Scientists are finding that a high intake of dietary spermidine could slow down (or reverse) the brain aging process. Memory loss and slower brain function...
Supplement report

Editor's picks

Dyno Therapeutics closes $100m to accelerate gene therapy

Dyno Therapeutics closes $100 million Series A led by Andreessen Horowitz to accelerate AI-powered gene therapy platform. Dyno Therapeutics, Inc, a biotech applying AI to...

Sticking with glutathione could be a smart longevity choice

The body's "master antioxidant" glutathione is a powerful weapon in the fight for longevity, but it diminishes with age; AgelessRx has a range of...

Rise of the retrons – a new gene editing technique

Move over CRISPR... a new gene editing technique enables millions of genetic experiments to be performed simultaneously. Like the best B Movie ever, The Day...
metformin

Pivotal study finds that telomere length lacks association with aging, yet frailty reflects mortality.

It is no secret that global populations demographics are aging significantly [1]. While the economic burden on younger adults to support the aging populations is a growing concern, it is important to note that the age of an individual is not reflective of their productivity in society [2]. So let’s talk telomere length (again):

Longevity.Technology: Chronological age reflects the time someone has lived since birth. Functional age, like biological age, is a concept describing the biological condition of tissues, organs and thus reflecting life expectancy. One proposed clinical biomarker studied in Longevity research is telomere length (TL). Telomeres have been a research focus, but perhaps, as some papers show, frailty is a better yardstick for Longevity.

Telomeres are protective DNA caps at the ends of every chromosome that slowly erode with age due to shortfalls of cellular replication machinery. A simple literature search however will reveal conflicting stances on the relevance of TL as an aging indicator.

Frailty is defined as a multi-systemic syndrome where there is a decrease in functionality, increased vulnerability to stress factors and increased risk of aging diseases. This is a well-establish marker for aging and mortality, and thus is accepted in the Longevity field.

Frailty is often measured by frailty phenotype (FP) proposed by the Cardiovascular Heart Study. Some characteristics include unintentional weight-loss of 4.5kg a year, exhaustion, weakness, slow walking speed, &c.

The relationship between TL and frailty remains unclear; on one hand, a 2018 study by Rosas-Vargas et al found a strong statistical correlation between frailty and TL in both males and females in a 323 Mexican cohort [3]. In contrast, similar studies in China did not find any correlation between the two factors [4].

Interestingly, a German study that did not find TL and frailty correlations found instead that epigenetics, frailty and senescence are closely related [5].

To clarify these conflicting reports, Professor Leocardio Rodriguez-Mañas and his team at the Hospital Universitario de Getafe evaluated whether or not TL has an association with frailty and mortality based on a Spanish community.

It is important to note that this was both a cross-sectional and longitudinal study, meaning it included a large sample of different individuals who were followed up with after a mean of 3.5 years. Additionally, two cohorts were analysed separately using the same parameters and adjustments, yielding the same conclusion based on meta-analysis.

 


 

“No association was found between TL and frailty or mortality … however, strong inverse correlation was found between frailty and mortality.”

 


 

Blood samples were analysed to calculate TL and physical performance was evaluated to determine FP according to CHS guidelines along with surveys on how an individual felt. No association was found between TL and frailty or mortality, even after age and sex statistical adjustments. However, strong inverse correlation was found between frailty and mortality [6].

While the results are quite definitive, the authors acknowledge that differences in study methodologies, as well as gender, age, demographic and socio-economic distributions may affect TL in ways that are not yet understood.

However, the study’s findings suggest that “in the elderly, telomere length is not especially worthy, assessed in terms of both physical function and longevity.” Better methods of reflecting functional age must be found to boost Longevity of individuals, in order to benefit society and quality of life.

[1] https://www.nber.org/digest/jul11/implications-population-aging-economic-growth
[2] https://hbr.org/2014/01/the-truth-about-aging-populations
[3] https://pubmed.ncbi.nlm.nih.gov/29989281/
[4] https://www.sciencedirect.com/science/article/pii/S0047637415300191
[5] https://clinicalepigeneticsjournal.biomedcentral.com/articles/10.1186/s13148-016-0186-5
[6] https://link.springer.com/article/10.1007/s11357-020-00291-0

 

Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.
metformin

Most popular

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

Spermidine: the mind-enhancing supplement

Scientists are finding that a high intake of dietary spermidine could slow down (or reverse) the brain aging process. Memory loss and slower brain function...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...
Supplement report

Related articles

Dyno Therapeutics closes $100m to accelerate gene therapy

Dyno Therapeutics closes $100 million Series A led by Andreessen Horowitz to accelerate AI-powered gene therapy platform. Dyno Therapeutics, Inc, a biotech applying AI to...

VitaDAO announces “Longevity Molecule” research project

VitaDAO will use advanced machine learning to crunch the data from 1.04 billion prescriptions to understand the impact of drugs on human lifespan. VitaDAO, which...

Harnessing the immune system to target cellular senescence

Deciduous Therapeutics aims for clinical trials of immune-activating senotherapeutic by 2023, with metabolic disease and fibrosis among potential indications. Californian start-up Deciduous Therapeutics has emerged...

Building a longevity biotech from scratch

Alchemab exec talks company creation and how antibody therapeutics may play a role in longevity biotech. Last week, we covered Alchemab Therapeutics’ $82 million Series...

Cellino: longevity powered by AI, stem cells & democracy

From a serendipitous meeting of minds to laser-enabled precision, Cellino is leveraging AI and pluripotent stem cells for longevity. We speak to CEO and...
metformin